Clinical Trials Browser

Phase 1 × Lymphoma × Lenalidomide × Clear all

NCT04301076 2026-04-13

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

Phase 1 Suspended

30 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04739813 2026-02-24

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Phase 1 Recruiting

55 enrolled

Lymphoid

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT01744912 2022-05-11

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

Phase 1 Terminated

10 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04818372 2021-11-12

Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

Phase 1 Unknown

87 enrolled

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT01542918 2020-08-11

Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma

Phase 1 Completed

14 enrolled

Lymphoid

Lymphoma, Recurrence, Intraocular Lymphoma

NCT01729104 2019-10-22

Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Phase 1 Terminated

18 enrolled

Lymphoid

Lymphoma, Recurrence, Lymphoma, Mantle-Cell

NCT01750762 2017-04-18

Lenalidomide After Allo Transplant

Phase 1 Terminated

1 enrolled

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT00864942 2015-03-13

Phase I BLR

Phase 1 Completed

28 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01005979 2014-08-13

A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)

Phase 1 Terminated

6 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00031941 2012-03-15

CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy

Phase 1 Completed

DermatologicLymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma